JPMorgan Chase & Co’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $603K | Buy |
34,560
+2,357
| +7% | +$41.1K | ﹤0.01% | 3979 |
|
|
2025
Q1 | $405K | Buy |
32,203
+1,091
| +4% | +$13.7K | ﹤0.01% | 4130 |
|
|
2024
Q4 | $328K | Sell |
31,112
-1,710
| -5% | -$18K | ﹤0.01% | 4337 |
|
|
2024
Q3 | $476K | Sell |
32,822
-178
| -0.5% | -$2.58K | ﹤0.01% | 4040 |
|
|
2024
Q2 | $281K | Sell |
33,000
-17,183
| -34% | -$146K | ﹤0.01% | 4103 |
|
|
2024
Q1 | $513K | Buy |
50,183
+15,534
| +45% | +$159K | ﹤0.01% | 3945 |
|
|
2023
Q4 | $190K | Buy |
34,649
+369
| +1% | +$2.02K | ﹤0.01% | 4468 |
|
|
2023
Q3 | $130K | Buy |
34,280
+11,746
| +52% | +$44.4K | ﹤0.01% | 4467 |
|
|
2023
Q2 | $151K | Buy |
22,534
+19,612
| +671% | +$131K | ﹤0.01% | 4435 |
|
|
2023
Q1 | $19K | Buy |
2,922
+350
| +14% | +$2.28K | ﹤0.01% | 5149 |
|
|
2022
Q4 | $22K | Buy |
2,572
+461
| +22% | +$3.94K | ﹤0.01% | 4953 |
|
|
2022
Q3 | $11K | Buy |
2,111
+614
| +41% | +$3.2K | ﹤0.01% | 5052 |
|
|
2022
Q2 | $6K | Sell |
1,497
-12,261
| -89% | -$49.1K | ﹤0.01% | 5272 |
|
|
2022
Q1 | $49K | Sell |
13,758
-158,066
| -92% | -$563K | ﹤0.01% | 5019 |
|
|
2021
Q4 | $1.14M | Buy |
171,824
+122,174
| +246% | +$813K | ﹤0.01% | 3583 |
|
|
2021
Q3 | $495K | Buy |
49,650
+40,555
| +446% | +$404K | ﹤0.01% | 3969 |
|
|
2021
Q2 | $281K | Sell |
9,095
-19,255
| -68% | -$595K | ﹤0.01% | 4323 |
|
|
2021
Q1 | $1.24M | Buy |
+28,350
| New | +$1.24M | ﹤0.01% | 3531 |
|